Abstract
PurposeSince 90’s Darby et all show as breast cancer radiotherapy appreciably increased mortality from heart disease and lung cancer 10–20 years afterwards with. Our aim is to investigate introduction of DIBH in breast cancer radiotherapy, comparing dose distribution with FB and to assess margin of error. MethodsFB and DIBH plans were performed using RayStation (RaySearch Laboratories) in 24 patients. DVH and dose statistics were compared, deformable registration performed to assess doses in DIBH and FB combined treatments. Perturbed dose in DIBH was computed to assess variability in the gating window (4 mm). ResultsDIBH plan showed a significant (p < 0.005) reduction in the mean dose of Heart, Left Ventricle and Left Anterior Descending Artery (LAD) respectively 54%, 62% and 64% and perturbed dose calculation in DIBH determined a variability in the respective mean dose of 27%, 28% and 24% in the gating window range of 4 mm. ConclusionsDIBH is a robust method to reduce radiation dose to the heart, and consequently reduce the heart disease mortality rate ratio [1]. Our method warranty total assessment in the dose variability due to the gating window and in case of DIBH interruption, the dose computation in DIBH and FB combined treatment, with the total control of heart doses.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
